53 related articles for article (PubMed ID: 3103876)
1. [A specific marker of thrombolysis: DDE complex].
Soria J; Soria C; Mirshahi M; Mirshahi M; Boucheix C; Pujade E; Perrot JY; Samama M; Bernadou A; Caen JP
C R Acad Sci III; 1987; 304(11):307-11. PubMed ID: 3103876
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma.
Koppert PW; Hoegee-de Nobel E; Nieuwenhuizen W
Thromb Haemost; 1988 Apr; 59(2):310-5. PubMed ID: 3133813
[TBL] [Abstract][Full Text] [Related]
3. Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction.
Soria J; Soria C; Mirshahi M; Xi M; Mirshahi M; Samama MM; Caen JP
Semin Thromb Hemost; 1987 Apr; 13(2):223-7. PubMed ID: 3114888
[TBL] [Abstract][Full Text] [Related]
4. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
[TBL] [Abstract][Full Text] [Related]
5. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction.
Lawler CM; Bovill EG; Stump DC; Collen DJ; Mann KG; Tracy RP
Blood; 1990 Oct; 76(7):1341-8. PubMed ID: 2119827
[TBL] [Abstract][Full Text] [Related]
6. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
[TBL] [Abstract][Full Text] [Related]
7. The detection of D-dimer in plasma by enzyme immunoassay: improved discrimination is obtained with a more specific signal antibody.
Hart R; Bate I; Dinh D; Elms M; Bundesen P; Hillyard C; Rylatt DB
Blood Coagul Fibrinolysis; 1994 Apr; 5(2):227-32. PubMed ID: 7519890
[TBL] [Abstract][Full Text] [Related]
8. The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA.
Eisenberg PR; Rylatt DB; Rusticali F; Ferrini D; Ottani F; Galvani M
Blood Coagul Fibrinolysis; 1997 Mar; 8(2):105-13. PubMed ID: 9518041
[TBL] [Abstract][Full Text] [Related]
9. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
[TBL] [Abstract][Full Text] [Related]
10. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies.
Raut S; Gaffney PJ
Thromb Haemost; 1996 Jul; 76(1):56-64. PubMed ID: 8819252
[TBL] [Abstract][Full Text] [Related]
12. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.
Dempfle CE; Dollman M; Lill H; Puzzovio D; Dessauer A; Heene DL
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):79-86. PubMed ID: 8457657
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
[TBL] [Abstract][Full Text] [Related]
14. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies.
Elms MJ; Bunce IH; Bundesen PG; Rylatt DB; Webber AJ; Masci PP; Whitaker AN
Thromb Haemost; 1983 Aug; 50(2):591-4. PubMed ID: 6356456
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.
Declerck PJ; Mombaerts P; Holvoet P; De Mol M; Collen D
Thromb Haemost; 1987 Dec; 58(4):1024-9. PubMed ID: 3127914
[TBL] [Abstract][Full Text] [Related]
16. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D dimer using EIA and latex test.
Hafter R; Schröck R; von Hugo R; Graeff H
Scand J Clin Lab Invest Suppl; 1985; 178():137-44. PubMed ID: 3867114
[TBL] [Abstract][Full Text] [Related]
17. Validation, calibration, and specificity of quantitative D-dimer assays.
Dempfle CE
Semin Vasc Med; 2005 Nov; 5(4):315-20. PubMed ID: 16302152
[TBL] [Abstract][Full Text] [Related]
18. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?
Itakura H; Sobel BE; Boothroyd D; Leung LL; Iribarren C; Go AS; Fortmann SP; Quertermous T; Hlatky MA;
Am Heart J; 2007 Dec; 154(6):1059-64. PubMed ID: 18035075
[TBL] [Abstract][Full Text] [Related]
19. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
20. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
